Deals
Ariad Shares Rise Amid Speculation of Potential Buyout
This article is for subscribers only.
Ariad Pharmaceuticals Inc., a takeover target last year before talks failed over the price, rose the most in a month on speculation that the drugmaker may be a buyout candidate yet again.
Posts on Twitter suggested that Ariad, a Cambridge, Massachusetts-based company developing oncology drugs, is a takeout target that would command a large premium. The shares climbed 6.5 percent to $12.90 at 3:24 p.m.